1. In this randomized controlled trial, inhaled fluticasone furoate did not shorten the time to recovery for non-hospitalized patients with mild-to-moderate coronavirus disease 2019 (COVID-19) compared to a placebo. 2. Adverse events were not common in the fluticasone furoate or the placebo group. Evidence Rating Level: 1 (Excellent) Study Rundown: As the COVID-19 pandemic continues,